Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097383 | 0.81 | MMP2 (0.50) | CA12CA9CA1CA2MAPK1 | |
| SCHEMBL6914203 | 0.81 | NPY2R (0.50) | NPY2RCA12CA9CA1CA2 | |
| SCHEMBL12373175 | 0.81 | NPY2R (0.50) | NPY2RCA12CA9CA1CA2 | |
| SCHEMBL11689700 | 0.81 | NPY2R (0.50) | NPY2RCA12CA9CA1CA2 | |
| SCHEMBL4830292 | 0.79 | NPY2R (0.49) | NPY2RCA12CA9CA1CA2 | |
| SCHEMBL519572 | 0.79 | NPY2R (0.46) | NPY2RCA12CA9CA1CA2 | |
| SCHEMBL6543930 | 0.78 | GAA (0.50) | NPY2RCA12CA9CA1CA2 | |
| SCHEMBL5776454 | 0.77 | MEN1 (0.51) | NPY2RCA12CA9CA1CA2 | |
| SCHEMBL14410815 | 0.77 | NPY2R (0.47) | NPY2RCA12CA9CA1CA2 | |
| SCHEMBL13848475 | 0.77 | NPY2R (0.47) | NPY2RCA12CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847534-B9 | Thiadiazoline derivatives for treating cancer | KYOWA HAKKO KIRIN CO LTD (JP) | 2012-03-21 | — | — | EP | disclosed |
| EP-1847534-B1 | Thiadiazoline derivatives for treating cancer | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-7902234-B2 | Thiadiazoline derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20100240716-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| US-7759371-B2 | Thiadiazoline derivative | Kyowa Hakko Kinn Co., Ltd. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-7425636-B2 | Thiadiazoline derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1847534-A2 | Thiadiazoline derivative | Kyowa Hakko Kogyo Co., Ltd (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070213380-A1 | Thiadiazoline derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20060074113-A1 | Thiadiazoline derivative | KYOWA KIRIN CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074113-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | NPY2R 3480/4885CA12 4720/4885CA9 4111/4885 |
| US-20070213380-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | NPY2R 3480/4885CA12 4720/4885CA9 4111/4885 |
| US-20100240716-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, WDR82, RB1 | NPY2R 3709/4885CA12 4611/4885CA9 4000/4885 |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, RB1, ARG2 | NPY2R 3480/4885CA12 4720/4885CA9 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.